Microba Life Sciences Limited (AU:MAP) has released an update.
Microba Life Sciences Limited, in partnership with Ginkro Bioworks, has successfully completed its groundbreaking autoimmune disease program, selecting six promising therapeutic leads from over 3 million data points for pre-clinical development. These leads have shown significant immunomodulatory effects in disease-relevant cell types, marking a significant advance in developing new treatments for autoimmune conditions. The company is now poised to progress these candidates into animal model efficacy assessments and clinical trial preparations.
For further insights into AU:MAP stock, check out TipRanks’ Stock Analysis page.
